1.80% 0.1599

Amneal Pharmaceuticals Inc (AMRX)

Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten

Amneal Pharmaceuticals Inc (AMRX)

Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten

Bank of New York Mellon Corp Increases Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat

Acadian Asset Management LLC Acquires 710,598 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat

J.P.Morgan upgrades Amneal Pharmaceuticals to “Neutral” - TradingPedia

Opioid Overdose Treatment Market is Projected to Reach US$ 3.1 Billion by 2034 | Fact.MR Report - GlobeNewswire Inc.

Organon downgraded, Amneal upgraded as J.P. Morgan reviews specialty pharma - MSN

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Position Reduced by Allspring Global Investments Holdings LLC - MarketBeat

Amneal and Shilpa Medicare announce US FDA approval of ready-to-use oncology product - BSI bureau

Analysts Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Target Price at $9.00 - MarketBeat

JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability - Benzinga

Amneal raised to neutral by J.P. Morgan amid improved growth - MSN

Amneal Pharmaceuticals (NASDAQ:AMRX) Upgraded to "Neutral" by JPMorgan Chase & Co. - MarketBeat

JP Morgan Upgrades Amneal Pharmaceuticals (AMRX) - MSN

Organon stock downgraded at J.P. Morgan (NYSE:OGN) - Seeking Alpha

Amneal stock upgraded as biosimilars and complex generics drive growthJPMorgan - Investing.com

FDA approves Amneal and Shilpa’s oncology product BORUZU - Pharmaceutical Technology

AMRXAmneal Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Amneal Stock Rises 29% in a Month on Upbeat Regulatory Updates - MSN

Amneal gains FDA approval for new oncology drug BORUZU - Investing.com

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration - Yahoo Finance UK

, the First Ready-to-Use Version of Bortezomib for subcutaneous administration - Business Wire

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration - StockTitan

Jackson Creek Investment Advisors LLC Acquires Shares of 161,760 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat

Convergence Investment Partners LLC Makes New Investment in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat

Amneal Stock Rises 29% in a Month on Upbeat Regulatory Updates - Zacks Investment Research

Amneal Stock Rises 29% in a Month on Upbeat Regulatory Updates - Nasdaq

Hussman Strategic Advisors Inc. Buys New Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat

Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 52-Week High at $8.45 - Defense World

Amneal Pharmaceuticals (NASDAQ:AMRX) Hits New 52-Week High at $8.45 - MarketBeat

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stake Boosted by Nisa Investment Advisors LLC - Defense World

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stake Boosted by Nisa Investment Advisors LLC - MarketBeat

Solid Organ Transplant Market is Projected to Grow at a 4.9% CAGR, Reaching $7.88 Billion by 2034 | Fact.MR Report - GlobeNewswire Inc.

Despite Fast-paced Momentum, Amneal (AMRX) Is Still a Bargain Stock - Yahoo Canada Finance

Amneal receives FDA approval for generic propofol - Investing.com

Amneal receives FDA approval for generic propofol By Investing.com - Investing.com Australia

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials - Winchester Herald Chronicle

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials - Business Wire

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials - StockTitan

Amneal Pharmaceuticals (NASDAQ:AMRX) Sets New 12-Month High at $8.16 - MarketBeat

Cancer-causing benzene found in some generic cold medicine - NewsNation Now

Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia - Yahoo Finance

Trade Alert: Executive VP & Chief Human Resources Officer Of Amneal Pharmaceuticals Nikita Shah Has Sold Stock - Simply Wall St

Amneal Pharmaceuticals EVP Shah Nikita sells $775,000 in stock By Investing.com - Investing.com Australia

Amneal Pharmaceuticals EVP Shah Nikita sells $775,000 in stock - Investing.com India

Insider Sale at Amneal Pharmaceuticals Inc (AMRX) by Executive Vice President Andrew Boyer By GuruFocus - Investing.com Canada

Amneal Pharmaceuticals EVP Shah Nikita sells $775,000 in stock - Investing.com

Amneal Pharmaceuticals EVP Shah Nikita sells $775,000 in stock By Investing.com - Investing.com UK

Pericarditis Drugs Global Strategic Business Report 2023-2030: Patent Expiries and Surge of Generics in the Market, Increasing Incidence of Cardiac Disorders Driving Demand - GlobeNewswire Inc.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by California State Teachers Retirement System - Defense World

Insider Sale at Amneal Pharmaceuticals Inc (AMRX): Executive Vice President Nikita Shah Sells ... By GuruFocus - Investing.com Canada

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $8.50 Consensus Target Price from Brokerages - Defense World

Is Sensus Healthcare (SRTS) Outperforming Other Medical Stocks This Year? - Yahoo Finance UK

Price T Rowe Associates Inc. MD Acquires 5,146 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Amneal Pharmaceuticals (NASDAQ:AMRX) Given New $10.00 Price Target at Barclays - Defense World

Store-Brand Mucinex Maker to Move Away from Using Cancer-Causing Chemical - Bloomberg

Barclays Increases Amneal Pharmaceuticals (NASDAQ:AMRX) Price Target to $10.00 - MarketBeat

Amneal Receives FDA Approval for Parkinson’s Treatment - European Pharmaceutical Manufacturer

Store-Brand Mucinex Maker to Move Away from Using Cancer-Causing Chemical - BNN Bloomberg

Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price Down 5.1% - MarketBeat

Generic version of Mucinex sold by CVS, Walmart, Walgreens and Target contains cancer-causing chemical: report - New York Post

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Truist Financial Raises Amneal Pharmaceuticals (NASDAQ:AMRX) Price Target to $10.00 - MarketBeat

Truist Financial Raises Amneal Pharmaceuticals (NASDAQ:AMRX) Price Target to $10.00 - Defense World

Cancer-Causing Benzene Is Used to Make Store-Brand Cold Relief Medicine - Bloomberg

Amneal Pharmaceuticals Second Quarter 2024 Earnings: EPS: US$0.019 (vs US$0.078 in 2Q 2023) - Yahoo Finance

Ähnlich wie AMRX